Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats

Acta Pharmacologica Sinica

Volumn 33, Issue 2, 2012, Pages 194-200

  Hansen, Gitte ^a   Jelsing, Jacob ^a   Vrang, Niels ^a  

^a Gubra ApS   (Denmark)

Author keywords

5 hydroxytryptamine (5 HT); diet induced obese rats; food preference; glucagon like peptide 1 (GLP 1); glucose tolerance; liraglutide; obesity; sibutramine

Indexed keywords

LIRAGLUTIDE; SIBUTRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; FOOD INTAKE; FOOD PREFERENCE; GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID DIET; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OBESITY; PALATABILITY; RAT; SUGAR INTAKE; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; CYCLOBUTANES; EATING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; MALE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84856880705     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.168     Document Type: Article

References (37)

1. Procter KL. The aetiology of childhood obesity: a review. Nutr Res Rev 2007; 20: 29-45. (Pubitemid 46978250)
2. Wang Y. Cross-national comparison of childhood obesity: the epidemic and the relationship between obesity and socioeconomic status. Int J Epidemiol 2001; 30: 1129-36. (Pubitemid 33049052)
3. Carroll L, Voisey J, van Daal A. Mouse models of obesity. Clin Dermatol 2004; 22: 345-9. (Pubitemid 39314622)
4. Kennedy AJ, Ellacott KL, King VL, Hasty AH. Mouse models of the metabolic syndrome. Dis Model Mech 2010; 3: 156-66.
5. Farooqi IS. Genetic, molecular and physiological insights into human obesity. Eur J Clin Invest. 2011; 41: 451-5.
6. Travers and McCarthy 2011
7. Levin BE, Dunn-Meynell AA, Balkan B, Keesey RE. Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol 1997; 273: R725-730.
8. Levin BE, Keesey RE. Defense of differing body weight set points in diet-induced obese and resistant rats. Am J Physiol 1998; 274: R412-419.
9. Archer ZA, Rayner DV, Rozman J, Klingenspor M, Mercer JG. Normal distribution of body weight gain in male Sprague-Dawley rats fed a high-energy diet. Obes Res 2003; 11: 1376-83. (Pubitemid 41127360)
10. Madsen AN, Hansen G, Paulsen SJ, Lykkegaard K, Tang-Christensen M, Hansen HS, et al. Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J Endocrinol 2010; 206: 287-96.
11. Levin BE, Triscari J, Hogan S, Sullivan AC. Resistance to diet-induced obesity: food intake, pancreatic sympathetic tone, and insulin. Am J Physiol 1987; 252: R471-8.
12. Smith BK, Kelly LA, Pina R, York DA, Bray GA. Preferential fat intake increases adiposity but not body weight in Sprague-Dawley rats. Appetite 1998; 31: 127-39. (Pubitemid 28502274)
13. Smith BK, Andrews PK, West DB. Macronutrient diet selection in thirteen mouse strains. Am J Physiol Regul Integr Comp Physiol 2000; 278: R797-805. (Pubitemid 30215190)
14. Raun K, von Voss P, Knudsen LB. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 2007; 15: 1710-6. (Pubitemid 47264950)
15. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56: 8-15.
16. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
17. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-16.
18. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-70. (Pubitemid 29418240)
19. Masek J, Fabry P. High-fat diet and the development of obesity in albino rats. Experientia 1959; 15: 444-5.
20. Mercer JG, Archer ZA. Diet-induced obesity in the Sprague-Dawley rat: dietary manipulations and their effect on hypothalamic neuropeptide energy balance systems. Biochem Soc Trans 2005; 33: 1068-72. (Pubitemid 41659115)
21. Sampey BP, Vanhoose AM, Winfeld HM, Freemerman AJ, Muehlbauer MJ, Fueger PT, et al. Cafeteria diet is a robust model of human metabolic syndrome with liver and adipose infammation: comparison to high-fat diet. Obesity (Silver Spring) 2011; 19: 1109-17.
22. Naderali EK, Williams G. Effects of short-term feeding of a highly palatable diet on vascular reactivity in rats. Eur J Clin Invest 2001; 31: 1024-8.
23. Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Merce R, et al. Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 2006; 148: 973-83. (Pubitemid 44543615)
24. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Schölmerich J, et al. Defning high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 2006; 36: 485-501. (Pubitemid 43904942)
25. Collins S, Martin TL, Surwit RS, Robidoux J. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 2004; 81: 243-8. (Pubitemid 38670090)
26. Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2006; 291: R367-75. (Pubitemid 44035643)
27. Blackburn G. Effect of degree of weight loss on health benefts. Obes Res 1995; 3: 211s-216s.
28. Follick MJ, Abrams DB, Smith TW, Henderson LO, Herbert PN. Contrasting short- and long-term effects of weight loss on lipoprotein levels. Arch Intern Med 1984; 144: 1571-4. (Pubitemid 14054474)
29. Yanovski SZ, Bain RP, Williamson DF. Report of a National Institutes of Health-Centers for Disease Control and Prevention workshop on the feasibility of conducting a randomized clinical trial to estimate the long-term health effects of intentional weight loss in obese persons. Am J Clin Nutr 1999; 69: 366-72. (Pubitemid 29104554)
30. Bray GA. Drug treatment of obesity. Rev Endocr Metab Disord 2001; 2: 403-18. (Pubitemid 33640589)
31. Boozer CN, Leibel RL, Love RJ, Cha MC, Aronne LJ. Synergy of sibutramine and low-dose leptin in treatment of diet-induced obesity in rats. Metabolism 2001; 50: 889-93. (Pubitemid 32755004)
32. Bush EN, Shapiro R, Brune ME, Knourek-Segel VE, Droz BA, Fev T, Lin E, Jacobsen PB. Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice. Endocrine. 2006; 29: 375-81. (Pubitemid 44097380)
33. Mashiko S, Ishihara A, Iwaasa H, Moriya R, Kitazawa H, Mitobe Y, et al. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine. Obesity 2008; 16: 1510-5. (Pubitemid 351915099)
34. Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes 2001; 50: 2530-9. (Pubitemid 33642771)
35. Halford JC. Lorcaserin - not a new weapon in the battle with appetite. Nat Rev Endocrinol 2010; 6: 663-4.
36. Olbers T, Bjorkman S, Lindroos A, Maleckas A, Lonn L, Sjostrom L, et al. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg 2006; 244: 715-22. (Pubitemid 44629945)
37. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008; 16: 298-305. (Pubitemid 351271908)